Immune-Mediated Skin Disease Program
Biologics | Targeted Orals | Phototherapy
Comprehensive assessment and advanced, pathway-targeted treatment for chronic immune-driven skin disease that has not responded adequately to topical or first-line systemic care.
Precision therapy for immune-driven skin disease.
Many chronic skin conditions are now understood as immune-driven diseases, the result of specific cytokine and signalling pathways that can be precisely targeted with modern therapy.
The program provides comprehensive assessment and advanced treatment for patients whose disease has not responded adequately to topical or first-line systemic care, with every patient assessed and followed by the same physician throughout treatment.
Conditions Managed
- Moderate-to-severe plaque psoriasis, including scalp, palmoplantar, and nail-predominant disease, and generalized pustular psoriasis
- Atopic dermatitis (eczema)
- Prurigo nodularis
- Chronic spontaneous urticaria
- Hidradenitis suppurativa
- Alopecia areata, including totalis and universalis
Therapies Offered
Treatment is matched to the underlying disease pathway, patient comorbidities, and personal goals.
Biologic therapies
Targeted monoclonal antibodies that block the specific cytokines driving psoriasis, atopic dermatitis, prurigo nodularis, chronic urticaria, hidradenitis suppurativa, and pustular psoriasis.
- IL-17
- IL-23
- IL-4/13
- IL-31
- IL-36
- TNF-alpha
- IgE
Targeted oral small molecules
A rapidly expanding class that complements biologics, selected by disease and patient profile across psoriasis, atopic dermatitis, and alopecia areata.
- JAK inhibitors
- TYK2 inhibitors
- PDE4 inhibitors
Conventional systemics and phototherapy
Established systemic agents and in-clinic light therapy that remain valuable for selected patients and integrate with newer options.
- Methotrexate
- Cyclosporine
- Acitretin
- Narrowband UVB
How the Program Works
Care is delivered directly by Dr. Maksym Breslavets, a Royal College-certified dermatologist with more than two decades in advanced therapeutics and prescribing experience across the major biologic classes used in dermatology. Every patient is assessed and followed by the same physician throughout treatment, supporting consistent decision-making across what are frequently multi-year disease courses.
Pathway-based selection
Therapy is matched to the cytokine pathway driving the disease, guided by current evidence rather than sequential trial and error.
Safety monitoring
Baseline workup and ongoing monitoring follow Canadian Dermatology Association guidance for each therapeutic class.
Drug-access support
Support spans manufacturer patient programs, private and public reimbursement navigation, and compassionate access where applicable.
Comorbidity screening
Screening covers the cardiometabolic, musculoskeletal, and psychosocial conditions associated with immune-mediated skin disease.
Dr. Breslavets is Principal Investigator and Registry Director of the Concurrent Biologics Registry, an independent, open-access quality assurance initiative documenting real-world outcomes of concurrent biologic therapy, with no pharmaceutical industry funding.
biologicsregistry.orgExplore More
Other Specialty Clinics
Referrals
Family physicians and specialists can refer using the CMSD referral form, selecting the relevant condition such as psoriasis, eczema, or alopecia areata. Severe flares can be marked URGENT for assessment within two weeks.
Learn about the referral process
Specialized dermatologic care, coordinated by one physician
Specialty clinic care is accessed through a referral from your family physician or specialist. Assessment, treatment, and follow-up are coordinated directly with your referring provider.